Patents Assigned to Epix Pharmaceuticals, Inc.
-
Publication number: 20120088749Abstract: The present invention relates to amides that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.Type: ApplicationFiled: December 16, 2011Publication date: April 12, 2012Applicants: EPIX PHARMACEUTICALS, INC., AMGEN, INC.Inventors: Susana C. Neira, Xiang Yu, Roland Burli, Victor Cee, Brian Lanman
-
Patent number: 8080542Abstract: The present invention relates to amides that have activity as SIP receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.Type: GrantFiled: September 19, 2008Date of Patent: December 20, 2011Assignees: Amgen, Inc., Epix Pharmaceuticals, Inc.Inventors: Susana C. Neira, Xiang Yu, Roland Burli, Victor Cee, Brian Lanman
-
Publication number: 20110212940Abstract: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.Type: ApplicationFiled: February 25, 2011Publication date: September 1, 2011Applicant: EPIX PHARMACEUTICALS, INC.Inventors: Roland Burli, Victor J. Cee, Jennifer Golden, Brian Alan Lanman, Susana Neira, Ashis Saha, Nili Schutz, Xiang Yu, Dilara McCauley, Mercedes Lobera, Yael Marantz, Jian Lin, Srinivasa R. Cheruku, Pini Orbach, Anurag Sharadendu, Robert C. Penland, Kimberley Gannon, Sharon Shacham, Silvia Noiman, Oren Becker, Zhaoda Zhang
-
Patent number: 7919519Abstract: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.Type: GrantFiled: March 21, 2007Date of Patent: April 5, 2011Assignee: Epix Pharmaceuticals Inc.Inventors: Roland Burli, Victor J. Cee, Jennifer Golden, Brian Alan Lanman, Susana Neira, Ashis Saha, Nili Schutz, Xiang Yu, Dilara McCauley, Mercedes Lobera, Yael Marantz, Jian Lin, Srinivasa R. Cheruku, Pini Orbach, Anurag Sharadendu, Robert C. Penland, Kimberley Gannon, Sharon Shacham, Silvia Noiman, Oren Becker, Zhaoda Zhang
-
Publication number: 20110059945Abstract: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.Type: ApplicationFiled: November 12, 2010Publication date: March 10, 2011Applicant: EPIX PHARMACEUTICALS, INC.Inventors: Ashis K. Saha, Nili Schutz, Xiang Yu, Dilara McCauley, Mercedes Lobera, Yael Marantz, Jian Lin, Srinivasa Cheruku, Pini Orbach, Anurag Sharadendu, Robert Christian Penland, Kimberley Gannon, Sharon Shacham, Silvia Noiman, Oren Becker
-
Patent number: 7855193Abstract: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.Type: GrantFiled: July 24, 2006Date of Patent: December 21, 2010Assignee: EPIX Pharmaceuticals, Inc.Inventors: Ashis K. Saha, Nili Schutz, Xiang Yu, Dilara McCauley, Mercedes Lobera, Yael Marantz, Jian Lin, Srinivasa R. Cheruku, Pini Orbach, Anurag Sharadendu, Robert Christian Penland, Kimberley Gannon, Sharon Shacham, Silvia Noiman, Oren Becker
-
Publication number: 20100317649Abstract: The present invention relates to compounds that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. In certain embodiments, the compounds of the invention relate to aryl oxoimidazolidinyls.Type: ApplicationFiled: August 24, 2010Publication date: December 16, 2010Applicant: EPIX PHARMACEUTICALS, INC.Inventors: Ashis Saha, Xiang Yu, Mercedes Lobera, Jian Lin, Srinivasa R. Cheruku, Oren Becker, Yael Marantz, Nili Schutz
-
Patent number: 7790707Abstract: The present invention relates to compounds that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. In certain embodiments, the compounds of the invention relate to aryl oxoimidazolidinyls.Type: GrantFiled: March 21, 2007Date of Patent: September 7, 2010Assignee: EPIX Pharmaceuticals Inc.Inventors: Ashis Saha, Xiang Yu, Mercedes Lobera, Jian Lin, Srinivasa R. Cheruku, Oren Becker, Yael Marantz, Nili Schutz
-
Patent number: 7412279Abstract: This invention relates to MRI-based methods and systems useful for diagnosing and clinically assessing the presence, location, and size of cardiovascular disease-associated stationary targets, e.g., thrombi and atherosclerotic lesions, within the vascular system. Methods and systems of the invention allow for improved anatomical information to be obtained from MRI images and allow the clinician to develop more effective treatment plans. In one aspect, the invention provides a method of determining the presence or absence of a stationary target within the vascular system of a mammal wherein two MRI data sets representing images of the vascular system and the stationary target are acquired after administration of a targeted MRI contrast agent. In another embodiment, both a targeted MRI contrast agent and a vascular MRI contrast agent are administered to a mammal, and both a vascular MRI and a targeted MRI data set are acquired.Type: GrantFiled: July 30, 2002Date of Patent: August 12, 2008Assignee: Epix Pharmaceuticals, Inc.Inventors: Robert M. Weisskoff, Peter D. Caravan, Sonia Witte, Randall B. Lauffer, Alan P. Carpenter, Jr.
-
Publication number: 20070185311Abstract: Peptides and peptide-targeted multimeric contrast agents are described, as well as methods of making and using the contrast agents.Type: ApplicationFiled: November 29, 2006Publication date: August 9, 2007Applicant: EPIX PHARMACEUTICALS, INC.Inventors: Zhaoda Zhang, John Amedio, Peter Caravan, Stephane Dumas, Andrew Kolodziej, Thomas McMurry
-
Patent number: 7238341Abstract: Peptides and peptide-targeted multimeric contrast agents are described, as well as methods of making and using the contrast agents.Type: GrantFiled: February 25, 2004Date of Patent: July 3, 2007Assignee: Epix Pharmaceuticals, Inc.Inventors: Zhaoda Zhang, John C. Amedio, Peter D. Caravan, Stephane Dumas, Andrew Kolodziej, Thomas J. McMurry
-
Patent number: 7229606Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.Type: GrantFiled: January 12, 2004Date of Patent: June 12, 2007Assignee: Epix Pharmaceuticals, Inc.Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
-
Patent number: 7186797Abstract: The present invention relates to compounds and methods for synthesizing compounds wherein the compounds exhibit extended circulating half-life in the blood. The increase in circulating half-life is achieved by conjugating polypeptides to binding groups that exhibit high affinity for human serum albumin.Type: GrantFiled: August 9, 2002Date of Patent: March 6, 2007Assignee: Epix Pharmaceuticals, Inc.Inventors: Theodore R. West, Thomas J McMurry, Stephane Dumas, Andrew Kolodziej
-
Patent number: 7175829Abstract: The present invention relates to a contrast-enhanced diagnostic imaging method for monitoring the efficacy of interventional therapies. The contrast agents useful in this method comprise an image-enhancing moiety (IEM) and a state-dependent tissue binding moiety (SDTBM). These contrast agents exhibit state-dependent binding to one or more components of a targeted tissue or tissue component and provide a detectable change in the signal characteristics of the agent once bound to the targeted tissue. As a result, these agents exhibit a binding affinity for, and thus image contrast of, the targeted tissue which changes as the tissue-state changes during therapy.Type: GrantFiled: October 8, 2004Date of Patent: February 13, 2007Assignee: Epix Pharmaceuticals, Inc.Inventors: Randall B. Lauffer, Stephen O. Dunham
-
Patent number: 7147837Abstract: The present invention relates to improved diagnostic agents for Magnetic Resonance Imaging and optical imaging. In particular, this invention relates to MRI and optical imaging agents that allow for the sensitive detection of a specific bioactivity within a tissue. These agents are prodrug contrast agents which are bioactivated in vivo in the presence of the specific bioactivity. This invention also relates to pharmaceutical compositions comprising these agents and to methods of using the agents and compositions comprising the agents.Type: GrantFiled: January 16, 2004Date of Patent: December 12, 2006Assignee: Epix Pharmaceuticals, Inc.Inventors: Randall B. Lauffer, Thomas J. McMurry, Stephen O. Dunham, Daniel M. Scott, David J. Parmelee, Stéphane Dumas
-
Patent number: 7060250Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.Type: GrantFiled: January 12, 2004Date of Patent: June 13, 2006Assignee: Epix Pharmaceuticals, Inc.Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
-
Patent number: 7011815Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.Type: GrantFiled: January 30, 2003Date of Patent: March 14, 2006Assignee: Epix Pharmaceuticals, Inc.Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
-
Patent number: 6969507Abstract: The present invention relates to methods for contrast-enhanced imaging of sexual response. In particular, the present invention relates to methods of magnetic resonance imaging (MRI), computerized X-ray tomography (CT), ultrasound, and optical imaging using contrast agents to measure blood flow during sexual response, especially female sexual response. The invention relates to methods of analyzing normal sexual function and sexual dysfunction and provides a means for evaluating and screening potential therapeutic compounds for enhancing sexual function or treating sexual dysfunction.Type: GrantFiled: November 8, 2002Date of Patent: November 29, 2005Assignee: Epix Pharmaceuticals, Inc.Inventors: Robert M. Weisskoff, Stephen C. Knight, Wayne Carter
-
Patent number: 6925321Abstract: A method is provided for improved visualization of vascular structures contained within magnetic resonance angiograms, particularly steady-state contrast-enhanced magnetic resonance angiograms. The disclosed methods include manipulating the relative enhancement levels of the arterial and venous blood pools images with respect to each other and to the surrounding anatomy. This manipulation is meant to optimize visualization of one or both of the individual blood pools without the necessity of completely obscuring or removing the supporting information given by presentation of the other blood pool and/or the surrounding anatomy.Type: GrantFiled: February 12, 2003Date of Patent: August 2, 2005Assignee: Epix Pharmaceuticals, Inc.Inventors: Robert M. Stefancik, Randy J. Earnest, Robert M. Weisskoff